These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 36251545)

  • 21. Obstacles to Biosimilar Acceptance and Uptake in Oncology: A Review.
    Mroczek DK; Hauner K; Greene GJ; Kaiser K; Peipert JD; Golf M; Kircher S; Shaunfield S; Lylerohr M; Cella D
    JAMA Oncol; 2024 Jul; 10(7):966-972. PubMed ID: 38814582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
    Cuellar S; McBride A; Medina P
    Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biosimilars in Oncology in the United States: A Review.
    Nabhan C; Parsad S; Mato AR; Feinberg BA
    JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overview of biosimilars for immune-mediated inflammatory diseases: summary of current evidence.
    Strand V; Evans C; Gibofsky A
    Am J Manag Care; 2022 Nov; 28(12 Suppl):S217-S226. PubMed ID: 36493395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analytic characterization of biosimilars.
    Sullivan PM; DiGrazia LM
    Am J Health Syst Pharm; 2017 Apr; 74(8):568-579. PubMed ID: 28389456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AMCP Partnership Forum: Biosimilars-policy, practice, and postmarketing surveillance to support treatment and coverage decisions.
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1503-1508. PubMed ID: 34459234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biosimilars: Opportunities to Promote Optimization Through Payer and Provider Collaboration.
    Manolis CH; Rajasenan K; Harwin W; McClelland S; Lopes M; Farnum C
    J Manag Care Spec Pharm; 2016 Sep; 22(9 Suppl):S3-9. PubMed ID: 27579939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The complexities of biosimilars and the regulatory approval process.
    Lucio S
    Am J Manag Care; 2018 Jun; 24(11 Suppl):S231-S236. PubMed ID: 29957908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products.
    Moore TJ; Mouslim MC; Blunt JL; Alexander GC; Shermock KM
    JAMA Intern Med; 2021 Jan; 181(1):52-60. PubMed ID: 33031559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biosimilars: biologics that meet patients' needs and healthcare economics.
    McCamish M; Yoon W; McKay J
    Am J Manag Care; 2016 Sep; 22(13 Suppl):S439-S442. PubMed ID: 28719221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An FDA perspective on the assessment of proposed biosimilar therapeutic proteins in rheumatology.
    Nikolov NP; Shapiro MA
    Nat Rev Rheumatol; 2017 Feb; 13(2):123-128. PubMed ID: 28053335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biosimilars for immune-mediated inflammatory diseases: a managed care perspective.
    Evans C; Gibofsky A; Strand V
    Am J Manag Care; 2022 Nov; 28(12 Suppl):S234-S239. PubMed ID: 36493397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biosimilars: A consideration of the regulations in the United States and European union.
    Daller J
    Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. US rheumatologists' beliefs and knowledge about biosimilars: a survey.
    Gibofsky A; McCabe D
    Rheumatology (Oxford); 2021 Feb; 60(2):896-901. PubMed ID: 33146388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Following the Biosimilar Breadcrumbs: When Health Systems and Manufacturers Approach Forks in the Road.
    Oskouei ST
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1245-1248. PubMed ID: 29172974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding State Regulation of Biosimilars and Effect on Prescribers.
    Yale K; Awosika O; Rengifo-Pardo M; Ehrlich A
    J Drugs Dermatol; 2017 Oct; 16(10):995-1000. PubMed ID: 29036253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Role of PD Biomarkers in Biosimilar Development - To Get the Right Answer One Must First Ask the Right Question.
    Woollett GR; Park JP; Han J; Jung B
    Clin Pharmacol Ther; 2023 Jan; 113(1):50-54. PubMed ID: 36148870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives.
    Baker JF; Leonard CE; Lo Re V; Weisman MH; George MD; Kay J
    Arthritis Rheumatol; 2020 Jul; 72(7):1067-1071. PubMed ID: 32253823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biosimilar Perceptions Among Healthcare Professionals and Commercial Medical Benefit Policy Analysis in the United States.
    Herndon K; Braithwaite J; Berry B; Bourget K
    BioDrugs; 2021 Jan; 35(1):103-112. PubMed ID: 33400238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.